Response to: Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus.
Mia RodziewiczSarah DyballSheilla AchiengSilke R BrixIan N BruceBen ParkerPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)